Aprea Therapeutics, Inc. (NASDAQ:APRE – Get Rating) – Research analysts at Wedbush boosted their Q1 2023 earnings per share estimates for shares of Aprea Therapeutics in a research note issued on Monday, August 15th. Wedbush analyst R. Driscoll now forecasts that the company will post earnings of ($0.10) per share for the quarter, up from their previous estimate of ($0.11). Wedbush has a "Outperform" rating and a $3.00 price target on the stock. The consensus estimate for Aprea Therapeutics' current full-year earnings is ($1.12) per share. Wedbush also issued estimates for Aprea Therapeutics' FY2023 earnings at ($0.45) EPS.

Aprea Therapeutics (NASDAQ:APRE – Get Rating) last released its quarterly earnings results on Monday, May 16th. The company reported ($0.36) EPS for the quarter, topping the consensus estimate of ($0.38) by $0.02.

Aprea Therapeutics Stock Performance

Hedge Funds Weigh In On Aprea Therapeutics

A number of institutional investors have recently made changes to their positions in APRE. Jane Street Group LLC acquired a new stake in shares of Aprea Therapeutics during the 2nd quarter valued at approximately $54,000. PDT Partners LLC grew its stake in Aprea Therapeutics by 62.5% during the 4th quarter. PDT Partners LLC now owns 142,600 shares of the company's stock worth $409,000 after buying an additional 54,866 shares during the last quarter. Magnus Financial Group LLC bought a new stake in Aprea Therapeutics in the fourth quarter valued at $98,000. Gyon Technologies Capital Management LP acquired a new position in shares of Aprea Therapeutics during the first quarter valued at $38,000. Finally, Renaissance Technologies LLC grew its position in shares of Aprea Therapeutics by 5.7% during the first quarter. Renaissance Technologies LLC now owns 297,900 shares of the company's stock worth $554,000 after acquiring an additional 15,977 shares during the last quarter. 16.46% of the stock is owned by institutional investors and hedge funds.

Aprea Therapeutics Company Profile

(Get Rating)

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors.

Recommended Stories

• Get a free copy of the StockNews.com research report on Aprea Therapeutics (APRE)
• If You Hate Speed Cameras, Then You'll Like Verra Mobility Stock
• Is Sanofi A Buy, Despite Recent Stumbles?
• Institutional Support For TJX Companies May Cap Gains
• Starbucks Stock, Is Brand Loyalty Enough Reason to Buy
• BJ's Wholesale Club Pops, Will Costco Be Next?

Receive News & Ratings for Aprea Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aprea Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.